Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5069 plus durvalumab for advanced hepatocellular carcinoma
ISRCTN12669009Phase 2Active, not recruiting
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Apr 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of azd5069 and durvalumab in hepatocellular carcinoma (HCC) (4 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoints: Recommended dose of AZD5069 in combination with durvalumab and Overall objective response rate. Started Apr 2022; status: active, not recruiting.
02
Drugs
azd5069durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ISRCTN12669009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12669009.